NCT05301894View on ClinicalTrials.gov

Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep

PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

June 7, 2022

Primary Completion Date

January 27, 2025

Study Completion Date

January 27, 2025

Conditions
Epileptic EncephalopathyContinuous Spike and Wave During Sleep
Interventions
DRUG

NBI-827104

T-type calcium channel blocker.

Trial Locations (12)

4293

Neurocrine Clinical Site, Dianalund

8032

Neurocrine Clinical Site, Zurich

20010

Neurocrine Clinical Site, Washington D.C.

27705

Neurocrine Clinical Site, Durham

28034

Neurocrine Clinical Site, Madrid

33155

Neurocrine Clinical Site, Miami

44195

Neurocrine Clinical Site, Cleveland

55905

Neurocrine Clinical Site, Rochester

80045

Neurocrine Clinical Site, Aurora

92868

Neurocrine Clinical Site, Orange

08950

Neurocrine Clinical Site, Barcelona

WC1N 3JH

Neurocrine Clinical Site, London

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY